EMEA cuts orphan drug fees
This article was originally published in Scrip
Executive Summary
In a move that should encourage the development of orphan drugs by micro-, small and medium-sized companies (SMEs), the European Medicines Agency has revised the fee structure for approval applications and post-authorisation activities.